RU2006113701A - Лечение респираторных заболеваний антителами против рецептора il-2 - Google Patents
Лечение респираторных заболеваний антителами против рецептора il-2 Download PDFInfo
- Publication number
- RU2006113701A RU2006113701A RU2006113701/15A RU2006113701A RU2006113701A RU 2006113701 A RU2006113701 A RU 2006113701A RU 2006113701/15 A RU2006113701/15 A RU 2006113701/15A RU 2006113701 A RU2006113701 A RU 2006113701A RU 2006113701 A RU2006113701 A RU 2006113701A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- named
- daclizumab
- use according
- amino acid
- Prior art date
Links
- 102000010789 Interleukin-2 Receptors Human genes 0.000 title claims 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 title claims 3
- 201000010099 disease Diseases 0.000 title claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 2
- 230000000241 respiratory effect Effects 0.000 title 1
- 229960002806 daclizumab Drugs 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000015768 polyposis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 241000272534 Struthio camelus Species 0.000 claims 1
- 210000004241 Th2 cell Anatomy 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 239000008362 succinate buffer Substances 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50588303P | 2003-09-23 | 2003-09-23 | |
| US60/505,883 | 2003-09-23 | ||
| US55297404P | 2004-03-12 | 2004-03-12 | |
| US60/552,974 | 2004-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006113701A true RU2006113701A (ru) | 2007-11-10 |
Family
ID=34396276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006113701/15A RU2006113701A (ru) | 2003-09-23 | 2004-09-21 | Лечение респираторных заболеваний антителами против рецептора il-2 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050089517A1 (enExample) |
| EP (1) | EP1675615A1 (enExample) |
| JP (1) | JP2007506681A (enExample) |
| AU (1) | AU2004275860A1 (enExample) |
| BR (1) | BRPI0414688A (enExample) |
| CA (1) | CA2538737A1 (enExample) |
| RU (1) | RU2006113701A (enExample) |
| WO (1) | WO2005030252A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004289252C1 (en) | 2003-11-08 | 2013-06-20 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use |
| AU2009260822B2 (en) | 2008-05-28 | 2016-09-22 | Prothera Biologics, Inc. | Preparation and composition of Inter-alpha inhibitor proteins from blood |
| AU2009325088B2 (en) * | 2008-12-10 | 2014-06-19 | Duke University | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| US9291626B2 (en) | 2011-05-12 | 2016-03-22 | Temple University—Of the Commonwealth System of Higher Education | Diagnosis and treatment of chronic obstructive pulmonary disease (COPD) |
| WO2014039987A2 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
| EP3512539A4 (en) | 2016-09-13 | 2020-07-29 | Prothera Biologics, Inc. | METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS |
| WO2018112069A1 (en) | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
| BR112019022358A2 (pt) | 2017-04-25 | 2020-05-19 | Prothera Biologics Inc | métodos para quantificar proteínas inibidoras inter-alfa |
| WO2020140040A1 (en) * | 2018-12-29 | 2020-07-02 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
| CN114641283B (zh) * | 2019-10-04 | 2024-07-12 | R.P.谢勒技术有限责任公司 | 抗cd25抗体-美登素偶联物及其使用方法 |
| US12268847B1 (en) | 2021-02-10 | 2025-04-08 | Kaleo, Inc. | Devices and methods for delivery of substances within a medicament container |
| CN118370816A (zh) * | 2024-03-22 | 2024-07-23 | 中日友好医院(中日友好临床医学研究所) | Il-2/抗il-2抗体免疫复合物的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4473493A (en) * | 1981-04-29 | 1984-09-25 | Immunex Corporation | Hybridoma antibody which inhibits interleukin 2 activity |
| US4845198A (en) * | 1984-05-21 | 1989-07-04 | Immunex Corporation | Hybridoma antibody which binds IL-2 receptor |
| US5336489A (en) * | 1985-09-05 | 1994-08-09 | The Beth Israel Hospital Association | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
| WO1996032151A1 (en) * | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for fluticasone propionate |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| WO2000006604A2 (en) * | 1998-07-27 | 2000-02-10 | Novartis Ag | Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases |
| BR0208656A (pt) * | 2001-04-06 | 2004-08-10 | Univ Bristol | Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides |
| EA013677B1 (ru) * | 2002-11-15 | 2010-06-30 | Генмаб А/С | Человеческие моноклональные антитела против cd25 и их применение |
-
2004
- 2004-09-21 JP JP2006527166A patent/JP2007506681A/ja active Pending
- 2004-09-21 WO PCT/US2004/031640 patent/WO2005030252A1/en not_active Ceased
- 2004-09-21 BR BRPI0414688-3A patent/BRPI0414688A/pt not_active IP Right Cessation
- 2004-09-21 AU AU2004275860A patent/AU2004275860A1/en not_active Abandoned
- 2004-09-21 EP EP04785126A patent/EP1675615A1/en not_active Withdrawn
- 2004-09-21 RU RU2006113701/15A patent/RU2006113701A/ru not_active Application Discontinuation
- 2004-09-21 US US10/947,432 patent/US20050089517A1/en not_active Abandoned
- 2004-09-21 CA CA002538737A patent/CA2538737A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2538737A1 (en) | 2005-04-07 |
| AU2004275860A1 (en) | 2005-04-07 |
| EP1675615A1 (en) | 2006-07-05 |
| BRPI0414688A (pt) | 2006-11-28 |
| JP2007506681A (ja) | 2007-03-22 |
| US20050089517A1 (en) | 2005-04-28 |
| WO2005030252A1 (en) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Menzella et al. | Tailored therapy for severe asthma | |
| JP2020128375A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2010043089A5 (enExample) | ||
| JP2004536072A5 (enExample) | ||
| IL303337B1 (en) | Methods for treating chronic sinusitis with nasal polyps by adding an IL-4–R4 antagonist | |
| JP2017507139A5 (enExample) | ||
| CN104755495A (zh) | 通过施用il-4r拮抗剂治疗或预防哮喘的方法 | |
| CN112153982A (zh) | 用于通过施用il-4r抑制剂治疗特应性皮炎的方法 | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| US20250034272A1 (en) | Compositions and methods for treating severe asthma | |
| JP2019529560A (ja) | Ｉｌ−４ｒ阻害剤を投与することによって重度のアトピー性皮膚炎を処置するための方法 | |
| WO2021195530A1 (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| JP2007506681A5 (enExample) | ||
| KR20250007566A (ko) | Fcrn 길항제를 사용한 수포성 유천포창을 치료하는 방법 | |
| JP2016527326A (ja) | ベンラリツマブによる喘息症状の改善方法 | |
| US20190322734A1 (en) | Treatment paradigm | |
| JP2014012683A5 (enExample) | ||
| TWI870471B (zh) | 全身性硬化症治療用醫藥組合物 | |
| KR20250094658A (ko) | 항체, 조성물 및 치료 방법 | |
| IL285483B (en) | Methods for the treatment of chronic sinusitis with nasal polyps by adding an il-4r antagonist | |
| CN114746444A (zh) | 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法 | |
| TW202337913A (zh) | 每週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法 | |
| CA3239667A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp | |
| RU2007139888A (ru) | Применение кальцитонина в качестве комбинированной терапии для лечения воспалительных болезненных состояний | |
| WO2025214333A1 (zh) | 抗tslp抗体治疗与tslp相关的炎症疾病的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090127 |